Susanne Malander
1 – 10 of 21
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
- Similarities and Differences of Blood N-Glycoproteins in Five Solid Carcinomas at Localized Clinical Stage Analyzed by SWATH-MS
- Claudin-4 Expression is Associated with Survival in Ovarian Cancer but Not with Chemotherapy Response
- Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy
- Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA) : results from a double-blind, phase 3, randomised controlled trial
- 2017
- Involvement of chromatin remodeling genes and the Rho GTPases RhoB and CDC42 in ovarian clear cell carcinoma
- 2016
- Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
- 2015
- Ovarialcancer är på många sätt en heterogen sjukdom
- Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival.
- 2014
- Distinct gene expression profiles in ovarian cancer linked to Lynch syndrome.
- Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypes.